Oncology Positron Emission Tomography Scan Industry Overview
Global Oncology Positron Emission Tomography Scan Market is segmented by Application (Cancer diagnosis, Tumor staging, Therapy response monitoring, Radiotherapy planning, Metastasis detection, Recurrence monitoring, Personalized oncology, Drug development research), Type (Hybrid PET/CT scanners, Digital PET systems, Time-of-flight PET, PET/MRI systems, Dedicated oncology PET scanners, Portable PET devices, Software and analytics platforms, Radiotracer manufacturing equipment), and Geography (North America, LATAM, West Europe, Central & Eastern Europe, Northern Europe, Southern Europe, East Asia, Southeast Asia, South Asia, Central Asia, Oceania, MEA)
Pricing
Report Overview
Industry Overview
The Oncology Positron Emission Tomography Scan market is witnessing significant growth and is expected to expand at a CAGR of 10% during the forecast period from 2025 to 2033. This growth is primarily driven by increasing technological advancements, rising consumer demand, and expanding applications across various industries. Businesses are increasingly adopting innovative solutions to improve operational efficiency, enhance customer experiences, and gain a competitive advantage, further fueling market expansion.
Source: HTF Market Intelligence (HTF MI)
Oncology PET scans offer high-resolution, functional imaging to visualize metabolic activity of tumors, facilitating accurate diagnosis, staging, and therapy response assessment. These scans employ radiotracers to detect cancer-specific biomarkers, enabling personalized treatment strategies and improved patient outcomes.
The research study Oncology Positron Emission Tomography Scan Market gives readers information on tactical business choices and strategic planning that affect and stabilize the growth prediction in the Oncology Positron Emission Tomography Scan market. However, a few disruptive trends will have opposite and significant effects on the distribution among players and the growth of the Oncology Positron Emission Tomography Scan market. To give further advice on why certain developments in the Oncology Positron Emission Tomography Scan market would have a significant impact and specifically why these trends can be taken into account when determining the market's trajectory and industry participants' strategic plans.
Key Highlights
• The Oncology Positron Emission Tomography Scan is growing at a CAGR of 10% during the forecasted period of 2025 to 2033
• Year-on-year growth for the market is 9.8%.
• Asia-Pacific dominated the market share in 2025
• Based on type, the market is bifurcated into the Hybrid PET/CT scanners, Digital PET systems, Time-of-flight PET, PET/MRI systems, Dedicated oncology PET scanners, Portable PET devices, Software and analytics platforms, Radiotracer manufacturing equipment segment, which dominated the market share during the forecasted period
• Based on application, the market is segmented into Application Cancer diagnosis, Tumor staging, Therapy response monitoring, Radiotherapy planning, Metastasis detection, Recurrence monitoring, Personalized oncology, Drug development research as the fastest-growing segment.
• North America, LATAM, West Europe, Central & Eastern Europe, Northern Europe, Southern Europe, East Asia, Southeast Asia, South Asia, Central Asia, Oceania, MEA import/export in terms of K tons, K units, and metric tons will be provided if applicable, based on industry best practices.
Market Dynamics Highlighted
Market Driver
The Oncology Positron Emission Tomography Scan market is experiencing significant growth due to various factors.
- • Increasing cancer incidence worldwide
- • growing adoption of precision oncology
- • advances in radiotracers and hybrid imaging technologies
- • demand for non-invasive diagnostic techniques.
Market Trend
The Oncology Positron Emission Tomography Scan market is growing rapidly due to various factors.
- • AI and machine learning integration for enhanced image interpretation
- • development of novel radiotracers targeting specific cancer types
- • expansion of PET/MRI hybrid scanners
- • increased use in immuno-oncology.
Opportunity
The Oncology Positron Emission Tomography Scan has several opportunities, particularly in developing countries where industrialization is growing.
Challenge
The market for fluid power systems faces several obstacles despite its promising growth possibilities.
Oncology Positron Emission Tomography Scan Market Segment Highlighted
Segmentation by Type
- • Hybrid PET/CT scanners
- • Digital PET systems
- • Time-of-flight PET
- • PET/MRI systems
- • Dedicated oncology PET scanners
- • Portable PET devices
- • Software and analytics platforms
- • Radiotracer manufacturing equipment
Segmentation by Application
- • Cancer diagnosis
- • Tumor staging
- • Therapy response monitoring
- • Radiotherapy planning
- • Metastasis detection
- • Recurrence monitoring
- • Personalized oncology
- • Drug development research
Key Players
The companies featured in this profile were selected based on insights from primary experts, evaluating their market penetration, product offerings, and geographical reach. By targeting emerging markets, these companies aim to leverage new opportunities, enhance their competitive advantage, and drive revenue growth. This approach not only aligns with their overall business objectives but also positions them to respond effectively to the evolving demands of consumers in these regions. Several key players in the Oncology Positron Emission Tomography Scan market are strategically focusing on expanding their operations in developing regions to capture a larger market share, particularly as the year-on-year growth rate for the market stands at 9.8%.
- • Siemens Healthineers (Germany)
- • GE Healthcare (USA)
- • Philips Healthcare (Netherlands)
- • Canon Medical Systems (Japan)
- • Spectrum Dynamics (Israel)
- • Mediso Medical Imaging (Hungary)
- • Bruker Corporation (USA)
- • Cardinal Health (USA)
- • Lantheus Medical Imaging (USA)
- • Telix Pharmaceuticals (Australia)
- • Jubilant Radiopharma (India)
- • Curium Pharma (France)
- • Eckert & Ziegler (Germany)
- • SOFIE Biosciences (USA)
- • Siemens (Germany)
- • GE (USA)
- • Philips (Netherlands)
- • Canon (Japan)
- • Spectrum Dynamics (Israel)
- • Mediso (Hungary)
- • Bruker (USA)
- • Cardinal (USA)
- • Lantheus (USA)
- • Telix (Australia)
- • Jubilant (India)
Regional Insight
The Asia-Pacific dominant region currently dominates the market share, fueled by increasing consumption, population growth, and sustained economic progress, which collectively enhance market demand. Conversely, the North America is growing rapidly, driven by significant infrastructure investments, industrial expansion, and rising consumer demand.
- North America
- LATAM
- West Europe
- Central & Eastern Europe
- Northern Europe
- Southern Europe
- East Asia
- Southeast Asia
- South Asia
- Central Asia
- Oceania
- MEA
- • Oncology PET scans have strong adoption in North America
Market Entropy
Merger & Acquisition
Patent Analysis
- • Patents cover novel radiotracers
Investment and Funding Scenario
- • Investment is strong from imaging companies
Report Infographics
| Report Features | Details |
| Base Year | 2025 |
| Based Year Market Size (2025) | 4.2 Billion |
| Historical Period | 2020 to 2025 |
| CAGR (2025 to 2033) | 10% |
| Forecast Period | 2026 to 2033 |
| Forecasted Period Market Size (2033) | 9 Billion |
| Scope of the Report |
By Type, By Application, By Region |
| Companies Covered | Siemens Healthineers (Germany), GE Healthcare (USA), Philips Healthcare (Netherlands), Canon Medical Systems (Japan), Spectrum Dynamics (Israel), Mediso Medical Imaging (Hungary), Bruker Corporation (USA), Cardinal Health (USA), Lantheus Medical Imaging (USA), Telix Pharmaceuticals (Australia), Jubilant Radiopharma (India), Curium Pharma (France), Eckert & Ziegler (Germany), SOFIE Biosciences (USA), Siemens (Germany), GE (USA), Philips (Netherlands), Canon (Japan), Spectrum Dynamics (Israel), Mediso (Hungary), Bruker (USA), Cardinal (USA), Lantheus (USA), Telix (Australia), Jubilant (India) |
| Customization Scope | 15% Free Customization
Want to Buy Specific Sections of This Report?
|
| Delivery Format | PDF and Excel through Email |
The Top-Down and Bottom-Up Approaches
The top-down approach begins with a broad theory or hypothesis and breaks it down into specific components for testing. This structured, deductive process involves developing a theory, creating hypotheses, collecting and analyzing data, and drawing conclusions. It is particularly useful when there is substantial theoretical knowledge, but it can be rigid and may overlook new phenomena.
Conversely, the bottom-up approach starts with specific data or observations, from which broader generalizations and theories are developed. This inductive process involves collecting detailed data, analyzing it for patterns, developing hypotheses, formulating theories, and validating them with additional data. While this approach is flexible and encourages the discovery of new phenomena, it can be time-consuming and less structured.
Regulatory Framework
The healthcare sector is overseen by various regulatory bodies that ensure the safety, quality, and efficacy of health services and products. In the United States, the U.S. Department of Health and Human Services (HHS) plays a crucial role in protecting public health and providing essential human services. Within HHS, the Food and Drug Administration (FDA) regulates food, drugs, and medical devices, ensuring they meet safety and efficacy standards. The Centers for Disease Control and Prevention (CDC) focuses on disease control and prevention, conducting research, and providing health information to protect public health.